Tag: Ocuphire Pharma


Ocuphire Pharma, Inc. (NASDAQ: OCUP) Announces Positive Outcome in VEGA-1 Phase 2 Trial in Presbyopia

Approximately 120 million Americans live with presbyopia, a gradual, age-related loss of the eyes’ ability to focus on nearby objects. And if nothing is done, the global is expected to exceed 150 million by 2034. Unfortunately, there are currently no approved drug therapies for this condition. However, Ocuphire Pharma, Inc. […]